3M Company (3M CO) - Q3 2006 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for the period ended September 30, 2006. 3M is a diversified global manufacturer operating in six segments: Industrial and Transportation, Health Care, Display and Graphics, Consumer and Office, Electro and Communications, and Safety, Security and Protection Services. The reporting period reflects a reorganization of business segments effective in Q1 2006 and the adoption of SFAS No. 123R (Share-Based Payment) effective January 1, 2006, which required the expensing of stock-based compensation.
Key Financial Metrics
| Metric | Q3 2006 | Q3 2005 | YTD 9M 2006 | YTD 9M 2005 |
|---|---|---|---|---|
| Net Sales | $5,858 million | $5,382 million | $17,141 million | $15,842 million |
| Operating Income | $1,342 million | $1,267 million | $3,886 million | $3,664 million |
| Net Income | $894 million | $840 million | $2,675 million | $2,365 million |
| Diluted EPS | $1.18 | $1.08 | $3.50 | $3.01 |
| Operating Margin | 22.9% | 23.5% | 22.7% | 23.1% |
| Operating Cash Flow (9M) | $2,517 million (vs. $3,038 million in 2005) | |||
| Total Debt | $3,800 million (as of Sept 30, 2006) | |||
| Cash & Equivalents | $999 million (as of Sept 30, 2006) | |||
| Working Capital | $1,446 million (as of Sept 30, 2006) |
Material Changes vs. Prior Period
- Sales Growth: Worldwide sales increased 8.8% in Q3 2006, driven by 6.5% organic volume growth and 1.7% from acquisitions. Local-currency sales grew 7.3%.
- Profitability: Operating income rose 5.9% year-over-year in Q3. However, operating margins declined from 23.5% to 22.9% due to higher stock-based compensation expenses and pharmaceutical transition costs.
- Stock-Based Compensation: Adoption of SFAS No. 123R and a change to a non-substantive vesting period for retirement-eligible employees increased stock option expense by $21 million in Q3 2006 compared to Q3 2005.
- Cash Flow: Operating cash flow decreased by $521 million year-over-year for the nine-month period, primarily due to higher tax payments ($400 million increase) and increased inventory levels.
- Debt Levels: Total debt increased significantly to $3.8 billion from $2.38 billion at year-end 2005, largely due to increased short-term debt (commercial paper) to fund share repurchases.
Guidance, Outlook, and Risks
- Pharmaceutical Business: 3M is actively seeking strategic alternatives for its branded pharmaceuticals business (approx. 20% of Health Care sales). The company incurred $13 million in transition costs in Q3 and expects additional expenses.
- Capital Allocation: The Board authorized an additional $1 billion in share repurchases in August 2006, bringing the total authorization to $3 billion. Approximately $1 billion remained available as of September 30, 2006. Dividends were increased by 9.5% in February 2006.
- Acquisitions: 3M completed 12 business combinations in the first nine months of 2006 for $468 million. A subsequent event noted the intent to purchase Brontes Technologies Inc. for $95 million, expected to result in a Q4 charge of $0.12-$0.13 per share for in-process R&D write-offs.
- Legal & Environmental: Significant ongoing litigation includes antitrust claims regarding transparent tape (settlements approved in Q3/Q4), respirator mask/asbestos claims (approx. 28,800 claimants), and environmental matters related to perfluorooctanyl compounds (PFOA/PFOS). The company has established reserves but cannot reliably estimate the full range of potential asbestos liabilities.
- Accounting Changes: Implementation of SFAS No. 158 (pension accounting) is expected to reduce stockholders' equity by approximately $2.3 billion (after-tax) in the fourth quarter of 2006, though it will not impact net income.
Investor Verification Checklist
- Pharmaceutical Divestiture: Monitor progress on the sale of the branded pharmaceuticals business and associated restructuring costs.
- Stock-Based Compensation Impact: Verify the ongoing impact of the non-substantive vesting period approach on quarterly earnings.
- Legal Reserves: Review updates on the respirator/asbestos litigation and the final approval of antitrust tape settlements.
- Environmental Liabilities: Track regulatory developments regarding PFOA/PFOS and associated remediation costs in Minnesota and Alabama.
- Debt Structure: Assess the sustainability of the increased short-term debt levels used to fund the $3 billion share repurchase program.
- Segment Performance: Analyze the margin compression in the Display and Graphics segment due to LCD pricing pressures and operational challenges.